Stepwise management of chronic kidney disease in primary care

Abstract

Get full access to this article

View all access options for this article.

References

Di Minno

Chiari

Castaldo

, et al. (2023) Effect of combination treatment with glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter-2 inhibitor on cardiovascular and renal outcomes: a meta-analysis. BMJ 385(8343): 078242. DOI: 10.1136/bmj-2023-078242.

Forbes

Brown

Chen

, et al. (2024) Implementation of chronic kidney disease guidelines for sodium–glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study. eClinicalMedicine 68: 102426. DOI: 10.1016/j.eclinm.2024.102426.

Herrington

Judge

Grams

, et al. (2026) Chronic kidney disease. Lancet 407(10523): 90–104. DOI: 10.1016/S0140-6736(25)01942-7.

Jadoul

Aoun

Imani

(2024) The major global burden of chronic kidney disease. Lancet Global Health 12(3): e342–e343. DOI: 10.1016/S2214-109X(24)00050-0.

Kidney Disease: Improving Global Outcomes (KDIGO) (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International 105(Suppl. 4S): S117–S314. DOI: 10.1016/j.kint.2023.10.018.

Kotwal

Perkovic

(2025) Effects of semaglutide on CKD in patients with type 2 diabetes. Kidney International Reports 10(2): 287–290. DOI: 10.1016/j.ekir.2024.11.1365.

Moncho

Benlloch

Górriz

(2025) The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Clinical Kidney Journal 18(9): sfaf260. DOI: 10.1093/ckj/sfaf260.

Neuen

Fletcher

Anker

, et al. (2025) SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA 335(3): 233–244. DOI: 10.1001/jama.2025.20834.

NHS England Digital (2022) Chronic kidney disease. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2022-part-2/kidney-disease (accessed 17 October 2025).

10.

NICE (2021) Chronic kidney disease: assessment and management (NG203). Available at: www.nice.org.uk/guidance/ng203 (accessed 17 October 2025).

11.

NICE (2023a) Empagliflozin for treating chronic kidney disease. NICE Technology appraisal guidance. TA942. Available from: www.nice.org.uk/guidance/ta942

12.

NICE (2023b) Finerenone for treating chronic kidney disease in type 2 diabetes. NICE Technology appraisal guidance. TA877. Available from: www.nice.org.uk/guidance/ta877

13.

NICE (2025). Dapagliflozin for treating chronic kidney disease. NICE Technology appraisal guidance TA1075. Available from: www.nice.org.uk/guidance/ta1075

14.

Perkovic

Tuttle

Rossing

, et al. (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine 391(2): 109–121. DOI: 10.1056/nejmoa2403347.

15.

RCGP (2025) Clinical topic guide: renal and urology. Available at: (accessed 16 February 2026). www.rcgp.org.uk/mrcgp-exams/gp-curriculum/renal-urology

16.

Song

Alexander

Prochaska

(2025) Delaying progression of chronic kidney disease. JAMA 334(7): 629–630. DOI: 10.1001/jama.2025.9532.

17.

The UK eCKD Guide (UK Kidney Association) (2024) UK eCKD Guide. Available at: www.ukkidney.org/health-professionals/information-resources/uk-eckd-guide (accessed 17 October 2025).